About 2 months ago, the media was full of news stories about a study called the Systolic Blood Pressure Intervention Trial (SPRINT). This media attention wasn’t because of the publication of a peer-reviewed article. It was because the National Institutes of Health held a media briefing about ending the trial early.
At the time, we knew that SPRINT was a randomized controlled trial of more aggressive targets for blood pressure control in adults aged 50 years or older with hypertension. Participants also had an increased risk of cardiovascular events but were excluded if they had diabetes, a history of stroke, or polycystic kidney disease. Patients were randomly assigned to treatment with a target of 120 mm Hg or 140 mm Hg systolic pressure. The main outcome of interest was cardiovascular outcomes and kidney disease.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.